The downgrade from Buy to Neutral by a major financial institution like Citigroup, accompanied by a significant reduction in the price target, is likely to negatively impact investor sentiment towards Bio-Rad Laboratories in the short term. This could lead to a decrease in the stock price as market participants adjust their expectations based on the new analyst rating and price target.